| Autor: |
Sillar JR; School of Biomedical Sciences and Pharmacy, The University of Newcastle, Callaghan, NSW 2308, Australia.; Haematology Department, Calvary Mater Hospital Newcastle, Waratah, NSW 2298, Australia.; NSW Health Pathology North- Hunter John Hunter Hospital, Newcastle, NSW 2305, Australia., Enjeti AK; Haematology Department, Calvary Mater Hospital Newcastle, Waratah, NSW 2298, Australia.; NSW Health Pathology North- Hunter John Hunter Hospital, Newcastle, NSW 2305, Australia.; School of Medicine and Public Health, The University of Newcastle, Callaghan, NSW 2308, Australia. |
| Abstrakt: |
Acute Myeloid Leukaemia is a devastating disease that continues to have a poor outcome for the majority of patients. In recent years, however, a number of drugs have received FDA approval, following on from successful clinical trial results. This parallels the characterization of the molecular landscape of Acute Myeloid Leukaemia (AML) over the last decade, which has led to the development of drugs targeting newly identified recurring mutations. In addition, basic biological research into the pathobiology of AML has identified aberrant programmed cell death pathways in AML. Following on from successful outcomes in lymphoid malignancies, drugs targeting the B Cell Lymphoma 2 (BCL-2) family of anti-apoptotic proteins have been explored in AML. In this review, we will outline the preclinical and clinical work to date supporting the role of drugs targeting BCL-2, with Venetoclax being the most advanced to date. We will also highlight rationale combinations using Venetoclax, ongoing clinical trials and biomarkers of response identified from the early phase clinical trials performed. |
